<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Overview of biologic agents in the rheumatic diseases</title><link href="/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/d/css/icofont.min.css" rel="stylesheet"/><link href="/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/d/css/animate.css" rel="stylesheet"/><link href="/d/css/owl.carousel.css" rel="stylesheet"/><link href="/d/css/magnific-popup.css" rel="stylesheet"/><link href="/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/d/css/style.css" rel="stylesheet"/><link href="/d/css/rtl_edited.css" rel="stylesheet"/><link href="/d/css/responsive.css" rel="stylesheet"/><link href="https://medilib.ir/uptodate_assets/main.css" rel="stylesheet">
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>

<meta content="" name="description"/>
<link href="/d/img/favicon.png" rel="icon" type="image/png"/>
</link></head>
<body>
<!-- Start Main Menu Area -->

<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>




<section class="teacher-area ptb-10">
<div class="container">
</div>

<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Overview of biologic agents in the rheumatic diseases</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="topicTitle">Overview of biologic agents in the rheumatic diseases</div> <div class="authorSectionElem"><div class="authorsElementsLeft"><dl id="topicContributors"><dt><span> </span>Author:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Gerd R Burmester, MD</a></dd><dt><span> </span>Section Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Daniel E Furst, MD</a></dd><dt><span> </span>Deputy Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Philip Seo, MD, MHS</a></dd></dl></div><div class="authorsElementsRight"><div id="literatureReviewDate"><div class="litReviewSingleLine"><bdi><span class="emphasis">Literature review current through:</span> Jan 2024.</bdi></div><div class="litReviewSingleLine"><bdi><span class="emphasis">This topic last updated:</span> Jan 11, 2024.</bdi></div></div></div></div><div id="topicWhatsNewContainer"></div><div id="topicText"><p class="headingAnchor" id="H1"><span class="h1">INTRODUCTION</span><span class="headingEndMark"> — </span>Advances in molecular biology, immunology, and drug development since the late 1990s have led to a variety of new treatment approaches to rheumatoid arthritis and other systemic inflammatory diseases associated with autoimmunity. The major biologic approaches in clinical use, including both medications made by molecular biologic techniques and small molecule kinase inhibitors, include agents that:</p><p class="bulletIndent1"><span class="glyph">●</span>Interfere with cytokine function, signal transduction, or production</p><p class="bulletIndent1"><span class="glyph">●</span>Inhibit the "second signal" required for T-cell activation</p><p class="bulletIndent1"><span class="glyph">●</span>Deplete B cells</p><p></p><p>An overview of biologic agents, biosimilar medications with near identity to the original biologic agents, and small molecule kinase inhibitors used in the management of patients with rheumatic disorders is reviewed here. The role of cytokines in the immune system and in rheumatic disease pathogenesis, the management strategies for individual diseases, and a fuller discussion of the efficacy and safety of these agents are presented in detail separately (see  <a class="medical medical_review" href="/d/html/3980.html" rel="external">"The adaptive cellular immune response: T cells and cytokines"</a>). (See relevant disease-specific topic reviews.)</p><p class="headingAnchor" id="H2"><span class="h1">T CELL SUBSETS AND CYTOKINES</span><span class="headingEndMark"> — </span>T helper (Th) cell subsets each secrete an array of specific cytokines, which then influence the development and perpetuation of systemic inflammation. Th cells and their cytokines can be categorized into two general subsets, termed Th1 and Th2, which differ in how they affect the immune system. The cytokines generated by Th1 or Th2 cells respectively inhibit the cellular function of the other phenotype [<a href="#rid1">1,2</a>]. Additional cell types, termed Th17 cells and regulatory T cells (T reg), have also been described. Th cell differentiation and function are described in detail separately. (See  <a class="medical medical_review" href="/d/html/3980.html" rel="external">"The adaptive cellular immune response: T cells and cytokines", section on 'Cytokine profiles and functions of CD4+ T helper cell subsets'</a>.)</p><p>Briefly, the following major subsets are important and of particular interest in the regulation of normal immune function and immune-mediated disorders:</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Th1 cells</strong> – Th1 lymphocytes participate in a broad variety of inflammatory responses, including cell-mediated inflammation in rheumatoid arthritis, psoriasis, psoriatic arthritis, acute allograft rejection, graft-versus-host disease, and others. Some of the proinflammatory mediators produced by Th1 cells include interferon gamma (IFNg), tumor necrosis factor (TNF), and interleukin (IL) 2. IFNg and IL-2 can inhibit Th2 cell proliferation.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Th2 cells</strong> – Th2 lymphocytes stimulate antibody production by B cells and augment eosinophil responses. The activation of Th2 cells contributes to the development of chronic graft-versus-host disease, systemic lupus erythematosus, and systemic sclerosis. A partial list of mediators produced by Th2 includes IL-4, -5, -10, and -13. IL-4 and IL-10 can inhibit Th1 cytokine production.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Th17 cells</strong> – Th17 cells differentiate from naïve T cells in response to antigen, transforming growth factor (TGF) beta, IL-6, and IL-23 [<a href="#rid3">3,4</a>]. Th17 cells secrete a cytokine, IL-17, which in concert with other cytokines affects inflammation, cartilage, and bone metabolism [<a href="#rid5">5</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>T reg cells</strong> – T reg cells function largely to regulate other T cells. They may have critical functions in multiple rheumatic diseases, including giant cell arteritis, granulomatosis with polyangiitis, rheumatoid arthritis, systemic lupus erythematosus, spondyloarthritis, Sjögren's disease, and other conditions. T reg cells also differentiate under the influence of antigen and TGF beta, and they have a protective function through IL-10 and TGF beta [<a href="#rid5">5</a>]. While not yet clinically tested as cell-based therapy, their capacity to reduce inflammation and autoimmunity are the subject of interest in this context.</p><p></p><p>A number of anti-cytokine therapies have been developed as therapeutic agents based in part on these observations.</p><p class="headingAnchor" id="H7"><span class="h1">ANTICYTOKINE APPROACHES</span><span class="headingEndMark"> — </span>Several specific anticytokine therapies for the treatment of autoimmune diseases have been introduced into clinical practice.</p><p class="headingAnchor" id="H8"><span class="h2">Nomenclature</span><span class="headingEndMark"> — </span>Abbreviations placed at the ends of the names of therapeutic agents convey specific information relating to their structure [<a href="#rid6">6</a>]:</p><p class="bulletIndent1"><span class="glyph">●</span>"-cept" refers to fusion of a receptor to the Fc part of human immunoglobulin G1 (IgG1)</p><p class="bulletIndent1"><span class="glyph">●</span>"-mab" indicates a monoclonal antibody (mAb)</p><p class="bulletIndent1"><span class="glyph">●</span>"-ximab" indicates a chimeric mAb</p><p class="bulletIndent1"><span class="glyph">●</span>"-zumab" indicates a humanized mAb</p><p class="bulletIndent1"><span class="glyph">●</span>"-umab" indicates a fully human mAb</p><p></p><p>In late 2021, an expanded collection of four suffixes was introduced to accommodate the increasing number of mAbs, to decrease sound-alikes, and to provide information about modifications to the immunoglobulin structure [<a href="#rid7">7</a>]. These suffixes are to be used instead of "mab" for mAbs developed from 2022 onward (see  <a class="medical medical_review" href="/d/html/3970.html" rel="external">"Overview of therapeutic monoclonal antibodies", section on 'Naming conventions'</a>):</p><p class="bulletIndent1"><span class="glyph">●</span>"tug" is used for full-length unmodified immunoglobulins that recognize a single epitope (monospecific)</p><p class="bulletIndent1"><span class="glyph">●</span>"bart" is used for full-length monospecific immunoglobulins with engineered constant regions or any point mutation introduced by engineering</p><p class="bulletIndent1"><span class="glyph">●</span>"mig" is used for bispecific or multispecific immunoglobulins with any structure</p><p class="bulletIndent1"><span class="glyph">●</span>"ment" is used for monospecific immunoglobulin variable region fragments</p><p></p><p class="headingAnchor" id="H9"><span class="h2">Types of therapeutic molecules</span><span class="headingEndMark"> — </span>To downregulate or inhibit the effector functions of cytokines in vivo, three general approaches have been used:</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Soluble receptor antagonists</strong> – Soluble receptor antagonists can be truncated forms of the cell surface receptor that are devoid of the transmembrane and intracytoplasmic domains. However, these molecules retain binding affinities that are comparable to those of full-length membrane-bound receptors. The prototypical soluble receptor antagonist is <a class="drug drug_general" data-topicid="8925" href="/d/drug information/8925.html" rel="external">etanercept</a>, a fusion protein comprised of the p75 tumor necrosis factor (TNF) receptor linked to the Fc portion of human IgG1. (See <a class="local">'Etanercept'</a> below.)</p><p></p><p class="bulletIndent1">Soluble receptor molecules such as <a class="drug drug_general" data-topicid="8925" href="/d/drug information/8925.html" rel="external">etanercept</a> bind their target cytokine while it is in serum, thereby inhibiting the cytokine's ability to interact with its cell surface receptors. Soluble fusion proteins must remain in the circulation for at least several days to achieve their therapeutic effects. The half-life of etanercept is longer than that of the native soluble receptor because the receptor binds tightly to the IgG-Fc [<a href="#rid8">8</a>]</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Monoclonal antibodies to cytokines or their receptors</strong> – The second approach to the downregulation of cytokine function has been the use of mAbs [<a href="#rid9">9</a>]. mAbs also have a higher affinity for a given cytokine compared with soluble receptors (eg, <a class="drug drug_general" data-topicid="8925" href="/d/drug information/8925.html" rel="external">etanercept</a>) that target the same molecule.</p><p></p><p class="bulletIndent1">Therapeutic mAbs used to treat patients with rheumatologic diseases typically consist of the Fc portion of human IgG1 (sometimes IgG4) and chimeric, humanized, or fully human Fab fragments. Examples of mAbs employed in the treatment of rheumatic disease are <a class="drug drug_general" data-topicid="8984" href="/d/drug information/8984.html" rel="external">infliximab</a>, <a class="drug drug_general" data-topicid="8583" href="/d/drug information/8583.html" rel="external">adalimumab</a>, <a class="drug drug_general" data-topicid="9514" href="/d/drug information/9514.html" rel="external">ustekinumab</a>, and <a class="drug drug_general" data-topicid="99569" href="/d/drug information/99569.html" rel="external">secukinumab</a>. Certolizumab, a polyethylene glycolated (PEGylated) Fab fragment that does not contain an Fc portion, has also been developed, as have other therapeutic antibodies derived from IgG2 and IgG4. (See <a class="local">'TNF inhibition'</a> below and <a class="local">'Ustekinumab'</a> below and <a class="local">'Secukinumab'</a> below.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Cell surface receptor antagonist proteins</strong> – Recombinant cell surface receptor antagonists are biologically inactive proteins that compete with a cytokine for binding to the cytokine's membrane receptor [<a href="#rid10">10</a>]. Examples of cell surface receptor antagonists in the rheumatic diseases are <a class="drug drug_general" data-topicid="9246" href="/d/drug information/9246.html" rel="external">anakinra</a> and <a class="drug drug_general" data-topicid="9483" href="/d/drug information/9483.html" rel="external">rilonacept</a>, recombinant antagonists of the interleukin (IL) 1 receptor (see <a class="local">'IL-1 inhibition'</a> below). Another mAb against a receptor is <a class="drug drug_general" data-topicid="112051" href="/d/drug information/112051.html" rel="external">brodalumab</a>, an anti-IL-17 receptor antibody. (See <a class="local">'IL-17 inhibition'</a> below.)</p><p></p><p class="bulletIndent1">Receptor antagonists must bind greater than 90 percent of the receptors on the cell surface to be effective. Large doses of the antagonist are required for such an effect.</p><p></p><p>Another approach, which more indirectly targets an array of cytokines, is the use of orally administered small molecule drugs, produced by traditional manufacturing techniques, which are designed to inhibit selected cytoplasmic protein tyrosine kinases, such as Janus kinase (JAK), which mediates signaling from membrane cytokine receptors. (See  <a class="medical medical_review" href="/d/html/130611.html" rel="external">"Overview of the Janus kinase inhibitors for rheumatologic and other inflammatory disorders"</a>.)</p><p class="headingAnchor" id="H842290356"><span class="h1">BIOLOGIC CYTOKINE INHIBITORS</span></p><p class="headingAnchor" id="H13"><span class="h2">TNF inhibition</span><span class="headingEndMark"> — </span>Five tumor necrosis factor (TNF) inhibitors are available for the treatment of rheumatoid arthritis and a number of other rheumatic and other immune-mediated diseases in the United States and worldwide. (See <a class="local">'Etanercept'</a> below and <a class="local">'Infliximab'</a> below and <a class="local">'Adalimumab'</a> below and <a class="local">'Certolizumab'</a> below and <a class="local">'Golimumab'</a> below.)</p><p>These drugs have been the subject of numerous trials and other studies, including multiple meta-analyses. As an example, a systematic literature review and meta-analysis of TNF-blocking agents for rheumatoid arthritis indicated that these agents used in monotherapy were equally efficacious and similar to <a class="drug drug_general" data-topicid="9630" href="/d/drug information/9630.html" rel="external">methotrexate</a> regarding clinical signs. When used in combination with methotrexate, they were better than methotrexate alone [<a href="#rid11">11</a>]. Thus, the combination of a TNF blocker and methotrexate was superior to either methotrexate or a TNF blocker alone, and the TNF blockers were relatively safe compared with methotrexate. The use and evidence for the efficacy of these agents in rheumatoid arthritis and other disorders are described in detail separately in the UpToDate topics on treatment of individual diseases, including rheumatoid arthritis, psoriatic arthritis and psoriasis, spondyloarthritis, inflammatory bowel disease, and others. (See appropriate topic reviews.)</p><p>The potential adverse effects of the TNF inhibitors are also described in detail separately. (See  <a class="medical medical_review" href="/d/html/7970.html" rel="external">"Tumor necrosis factor-alpha inhibitors: An overview of adverse effects"</a> and  <a class="medical medical_review" href="/d/html/7975.html" rel="external">"Tumor necrosis factor-alpha inhibitors: Risk of malignancy"</a> and  <a class="medical medical_review" href="/d/html/1410.html" rel="external">"Tumor necrosis factor-alpha inhibitors: Bacterial, viral, and fungal infections"</a> and  <a class="medical medical_review" href="/d/html/7974.html" rel="external">"Tumor necrosis factor-alpha inhibitors: Induction of antibodies, autoantibodies, and autoimmune diseases"</a>.)</p><p>Biosimilar forms of several TNF inhibitors have become commercially available in many countries, and additional biosimilar agents are in development. (See <a class="local">'Biosimilars for biologic agents'</a> below.)</p><p class="headingAnchor" id="H14"><span class="h3">Etanercept</span><span class="headingEndMark"> — </span><a class="drug drug_general" data-topicid="8925" href="/d/drug information/8925.html" rel="external">Etanercept</a> is a soluble p75 TNF receptor fusion protein that consists of two p75 TNF receptors bound to the Fc portion of immunoglobulin G (IgG). Thus, the medication is bivalent (one etanercept molecule binds two TNF molecules). Etanercept is administered once or twice weekly via subcutaneous injection.</p><p><a class="drug drug_general" data-topicid="8925" href="/d/drug information/8925.html" rel="external">Etanercept</a> is used for the treatment of a number of forms of inflammatory arthritis and other conditions, including juvenile idiopathic arthritis, rheumatoid arthritis, psoriatic arthritis, and ankylosing spondylitis. However, etanercept is not effective for ulcerative colitis and Crohn disease. (See appropriate topic reviews on the treatment of specific diseases.)</p><p>Biosimilars of <a class="drug drug_general" data-topicid="8925" href="/d/drug information/8925.html" rel="external">etanercept</a> have received regulatory approval in Europe, South Korea, and other countries [<a href="#rid12">12</a>]. (See <a class="local">'Biosimilars for biologic agents'</a> below.)</p><p class="headingAnchor" id="H15"><span class="h3">Infliximab</span><span class="headingEndMark"> — </span><a class="drug drug_general" data-topicid="8984" href="/d/drug information/8984.html" rel="external">Infliximab</a> is a chimeric monoclonal antibody (mAb) directed against TNF. The term "chimeric" refers to the use of both murine and human components of the drug. With infliximab, the kappa chain variable region (VK) and heavy chain variable region (VH) domains of the antigen-binding portion of the molecule are murine, and the constant Fc domain is human. Infliximab is administered via intravenous infusion approximately every six weeks once a steady state has been achieved.</p><p>The European Medicines Agency (EMA) and the Food and Drug Administration (FDA) approved a subcutaneous version of a biosimilar <a class="drug drug_general" data-topicid="8984" href="/d/drug information/8984.html" rel="external">infliximab</a>, which is also available in Canada and Korea [<a href="#rid13">13,14</a>].</p><p><a class="drug drug_general" data-topicid="8984" href="/d/drug information/8984.html" rel="external">Infliximab</a> is effective for the treatment of rheumatoid arthritis, ankylosing spondylitis, psoriatic arthritis, Crohn disease, and ulcerative colitis. (See appropriate topic reviews on the treatment of specific diseases.)</p><p>Biosimilar forms of <a class="drug drug_general" data-topicid="8984" href="/d/drug information/8984.html" rel="external">infliximab</a>, such as infliximab-dyyb, have been approved in a number of countries worldwide, with all the indications of the legacy (originator) compound [<a href="#rid12">12</a>]. (See <a class="local">'Biosimilars for biologic agents'</a> below.)</p><p class="headingAnchor" id="H16"><span class="h3">Adalimumab</span><span class="headingEndMark"> — </span><a class="drug drug_general" data-topicid="8583" href="/d/drug information/8583.html" rel="external">Adalimumab</a> is a recombinant fully human mAb that is administered subcutaneously rather than by intravenous infusion. The recommended interval between administrations is every two weeks. Adalimumab is associated with a lower risk of anti-drug antibody formation compared with <a class="drug drug_general" data-topicid="8984" href="/d/drug information/8984.html" rel="external">infliximab</a>, possibly by virtue of its fully human construction. Nevertheless, anti-drug antibodies occur upon treatment with adalimumab, which can be reduced by concomitant <a class="drug drug_general" data-topicid="9630" href="/d/drug information/9630.html" rel="external">methotrexate</a> treatment [<a href="#rid15">15</a>]. They are directed against the idiotype and can be neutralizing. (See  <a class="medical medical_review" href="/d/html/7974.html" rel="external">"Tumor necrosis factor-alpha inhibitors: Induction of antibodies, autoantibodies, and autoimmune diseases", section on 'Adalimumab-induced human anti-human antibodies'</a>.)</p><p><a class="drug drug_general" data-topicid="8583" href="/d/drug information/8583.html" rel="external">Adalimumab</a> has been approved for use in rheumatoid arthritis, plaque psoriasis, Crohn disease, pediatric Crohn disease, ulcerative colitis, psoriatic arthritis, hidradenitis suppurativa, ankylosing spondylitis, polyarticular juvenile idiopathic arthritis, and noninfectious intermediate, posterior, and panuveitis (see appropriate topic reviews on the treatment of specific diseases). Adalimumab biosimilars have been approved in numerous countries and regions, including in India [<a href="#rid12">12</a>], Canada, Europe [<a href="#rid16">16</a>], and the United States [<a href="#rid17">17</a>].</p><p class="headingAnchor" id="H17"><span class="h3">Certolizumab</span><span class="headingEndMark"> — </span><a class="drug drug_general" data-topicid="8644" href="/d/drug information/8644.html" rel="external">Certolizumab pegol</a> is a humanized anti-TNF-alpha antibody Fab' fragment that is chemically linked to polyethylene glycol. The medication neutralizes membrane-associated and soluble TNF-alpha. Certolizumab pegol is administered every two weeks by subcutaneous injection, and dosing at four-week intervals can be effective in some patients for maintenance therapy.</p><p><a class="drug drug_general" data-topicid="8644" href="/d/drug information/8644.html" rel="external">Certolizumab pegol</a> is formally approved in the United States for use in Crohn disease and rheumatoid arthritis, as well as psoriatic arthritis and ankylosing spondylitis, and it has been used in uveitis and ulcerative colitis. Like the other TNF inhibitors it is available worldwide. (See appropriate topic reviews on the treatment of specific diseases.)</p><p>In addition, the EMA has approved a label change for <a class="drug drug_general" data-topicid="8644" href="/d/drug information/8644.html" rel="external">certolizumab pegol</a>, making it the first anti-TNF for potential use in women with chronic rheumatic disease during both pregnancy and breastfeeding, based on two trials [<a href="#rid18">18,19</a>]. (See  <a class="medical medical_review" href="/d/html/7998.html" rel="external">"Safety of rheumatic disease medication use during pregnancy and lactation", section on 'Tumor necrosis factor inhibitors'</a>.)</p><p class="headingAnchor" id="H18"><span class="h3">Golimumab</span><span class="headingEndMark"> — </span><a class="drug drug_general" data-topicid="9086" href="/d/drug information/9086.html" rel="external">Golimumab</a> is a human IgG1 kappa mAb specific for human TNF-alpha that neutralizes TNF-alpha activity. Golimumab binds to both the soluble and transmembrane bioactive forms of human TNF-alpha. It is administered once monthly by subcutaneous injection.</p><p><a class="drug drug_general" data-topicid="9086" href="/d/drug information/9086.html" rel="external">Golimumab</a> has been available for use in patients with rheumatoid arthritis, psoriatic arthritis, ankylosing spondylitis and ulcerative colitis in a number of countries. (See appropriate topic reviews on the treatment of specific diseases.)</p><p class="headingAnchor" id="H19"><span class="h2">IL-1 inhibition</span><span class="headingEndMark"> — </span>Interleukin (IL) 1 inhibitors such as <a class="drug drug_general" data-topicid="9246" href="/d/drug information/9246.html" rel="external">anakinra</a> are available commercially for use in patients with rheumatoid arthritis and other forms of inflammatory arthritis. However, their relatively modest effect on inflammatory arthritis in rheumatoid arthritis compared with other biologic agents, such as the TNF inhibitors, has resulted in their being used only rarely for this disease. These agents are also used in systemic-onset juvenile idiopathic arthritis and adult-onset Still's disease, as well as other conditions. The biology, adverse effects, and other factors related to the various IL-1 inhibitors are discussed in detail separately. (See  <a class="medical medical_review" href="/d/html/127997.html" rel="external">"Interleukin 1 inhibitors: Biology, principles of use, and adverse events"</a>.)</p><p><a class="drug drug_general" data-topicid="9246" href="/d/drug information/9246.html" rel="external">Anakinra</a> and two other IL-1 inhibitors, <a class="drug drug_general" data-topicid="8906" href="/d/drug information/8906.html" rel="external">canakinumab</a> and <a class="drug drug_general" data-topicid="9483" href="/d/drug information/9483.html" rel="external">rilonacept</a>, through their effect on the inflammasome (a critical mediator of autoinflammatory conditions), are effective for the treatment of autoinflammatory conditions such as cryopyrin-associated periodic syndromes (CAPS), TNF receptor-1 associated periodic syndrome (TRAPS), and familial Mediterranean fever, and are used to treat these conditions. (See  <a class="medical medical_review" href="/d/html/5580.html" rel="external">"Tumor necrosis factor receptor-1 associated periodic syndrome (TRAPS)"</a> and  <a class="medical medical_review" href="/d/html/5585.html" rel="external">"Cryopyrin-associated periodic syndromes and related disorders"</a> and  <a class="medical medical_review" href="/d/html/2574.html" rel="external">"Management of familial Mediterranean fever", section on 'Interleukin 1 inhibition'</a>.)</p><p>IL-1 inhibition also has a role in the treatment of selected patients with acute gouty arthritis, as well as pseudogout. (See  <a class="medical medical_review" href="/d/html/1666.html" rel="external">"Treatment of gout flares", section on 'Resistant or refractory disease'</a> and  <a class="medical medical_review" href="/d/html/1671.html" rel="external">"Treatment of calcium pyrophosphate crystal deposition (CPPD) disease", section on 'Resistant disease'</a>.)</p><p>A variety of approaches to IL-1 inhibition, including receptor antagonism and IL-1 binding, have been employed.</p><p class="headingAnchor" id="H20"><span class="h3">Anakinra</span><span class="headingEndMark"> — </span><a class="drug drug_general" data-topicid="9246" href="/d/drug information/9246.html" rel="external">Anakinra</a> is a recombinant human IL-1 receptor antagonist (rHuIL-1Ra), which unlike the native protein is not glycosylated and has an additional N-terminal methionine. Anakinra is available for the treatment of rheumatoid arthritis but is significantly less potent in most patients with rheumatoid arthritis than TNF inhibitors [<a href="#rid20">20,21</a>]. Unlike conventional disease-modifying antirheumatic drugs (DMARDs; eg, <a class="drug drug_general" data-topicid="9630" href="/d/drug information/9630.html" rel="external">methotrexate</a>), anakinra is <strong>not</strong> recommended in a combination regimen with a TNF inhibitor or other biologic agents because of an increased frequency of serious adverse events, including serious infections [<a href="#rid22">22,23</a>]. (See  <a class="medical medical_review" href="/d/html/103866.html" rel="external">"Treatment of rheumatoid arthritis in adults resistant to initial biologic DMARD therapy", section on 'Resistant to standard therapies'</a>.)</p><p><a class="drug drug_general" data-topicid="9246" href="/d/drug information/9246.html" rel="external">Anakinra</a> may be more effective in the treatment of autoinflammatory conditions, including TRAPS (see  <a class="medical medical_review" href="/d/html/5580.html" rel="external">"Tumor necrosis factor receptor-1 associated periodic syndrome (TRAPS)"</a>). It is also used for the treatment of systemic juvenile idiopathic arthritis and adult-onset Still's disease, and in selected patients with recurrent pericarditis (see  <a class="medical medical_review" href="/d/html/6400.html" rel="external">"Systemic juvenile idiopathic arthritis: Treatment"</a> and  <a class="medical medical_review" href="/d/html/5595.html" rel="external">"Treatment of adult-onset Still's disease"</a> and  <a class="medical medical_review" href="/d/html/4944.html" rel="external">"Recurrent pericarditis", section on 'Other immune therapy'</a>). In the European Union, anakinra is approved to treat signs and symptoms of rheumatoid arthritis in combination with <a class="drug drug_general" data-topicid="9630" href="/d/drug information/9630.html" rel="external">methotrexate</a> in patients who have not responded adequately to methotrexate alone, and CAPS [<a href="#rid24">24</a>].</p><p><a class="drug drug_general" data-topicid="9246" href="/d/drug information/9246.html" rel="external">Anakinra</a> has also been approved by the US Food and Drug Administration (FDA) and EMA for the treatment of coronavirus disease 2019 (COVID-19). (See  <a class="medical medical_review" href="/d/html/127429.html" rel="external">"COVID-19: Management in hospitalized adults", section on 'Baricitinib and JAK inhibitors'</a>.)</p><p class="headingAnchor" id="H2717446"><span class="h3">Canakinumab</span><span class="headingEndMark"> — </span><a class="drug drug_general" data-topicid="8906" href="/d/drug information/8906.html" rel="external">Canakinumab</a>, an anti-IL-1beta (anti-IL-1b) mAb with a longer half-life than <a class="drug drug_general" data-topicid="9246" href="/d/drug information/9246.html" rel="external">anakinra</a>, has also been employed in autoinflammatory conditions and in settings in which IL-1 inhibition is beneficial (eg, acute gout in which contraindications to conventional therapies exist) [<a href="#rid25">25</a>].</p><p>In the United States and the European Union, <a class="drug drug_general" data-topicid="8906" href="/d/drug information/8906.html" rel="external">canakinumab</a> is approved for four types of periodic fever syndromes in adults and children aged two and above: CAPS, TRAPS, hyperimmunoglobulin D syndrome (HIDS)/mevalonate kinase deficiency (MKD), and familial Mediterranean fever; as well as for adult-onset Still's disease; systemic juvenile idiopathic arthritis (Still's disease; in children, aged two and above); and gouty arthritis [<a href="#rid26">26,27</a>].</p><p class="headingAnchor" id="H4094796688"><span class="h3">Rilonacept</span><span class="headingEndMark"> — </span><a class="drug drug_general" data-topicid="9483" href="/d/drug information/9483.html" rel="external">Rilonacept</a> is a human IgG1 Fc antibody with bispecific arms; these bind IL-1b. Like the other IL-1 inhibitors, it is available for use in patients with CAPS and related conditions such as the Muckle-Wells syndrome, another rare autoinflammatory disease. Although the manufacturer of rilonacept applied for FDA approval for gout, this approval was not granted. Nevertheless, like the other IL-1 inhibitors, it is sometimes used in this disease. Rilonacept is also approved for use in the United States for recurrent pericarditis. (See  <a class="medical medical_review" href="/d/html/5585.html" rel="external">"Cryopyrin-associated periodic syndromes and related disorders", section on 'Rilonacept'</a> and  <a class="medical medical_review" href="/d/html/4944.html" rel="external">"Recurrent pericarditis", section on 'Interleukin 1 inhibitors'</a>.)</p><p class="headingAnchor" id="H23"><span class="h2">IL-6 inhibition</span><span class="headingEndMark"> — </span>IL-6 has both proinflammatory and antiinflammatory effects and has been successfully targeted for the treatment of rheumatoid arthritis and other rheumatic diseases [<a href="#rid28">28</a>]. The cytokine activates T cells, B cells, macrophages, and osteoclasts and is a pivotal mediator of the hepatic acute phase response. In concert with TNF-alpha and IL-1, IL-6 promotes vascular endothelial growth factor (VEGF) and metalloproteinase production [<a href="#rid29">29</a>].</p><p>IL-6 binds to both soluble and membrane-bound receptors and leads to the transduction of intracellular signals through the interaction of this complex with gp130, mediating gene activation and a wide range of biologic activities [<a href="#rid29">29,30</a>].</p><p>The biology, principles of use, and adverse effects of therapeutic IL-6 inhibitors are described in detail separately. (See  <a class="medical medical_review" href="/d/html/129345.html" rel="external">"Interleukin 6 inhibitors: Biology, principles of use, and adverse effects"</a>.)</p><p class="headingAnchor" id="H24"><span class="h3">Tocilizumab</span><span class="headingEndMark"> — </span><a class="drug drug_general" data-topicid="10208" href="/d/drug information/10208.html" rel="external">Tocilizumab</a> is a humanized anti-human IL-6 receptor antibody of the IgG1 subclass. The medication is made by grafting the complementarity determining regions of a mouse anti-human IL-6 receptor mAb onto human IgG1. Tocilizumab binds to both the membrane-bound and soluble forms of human IL-6 receptor (IL-6R), thereby inhibiting the action of the cytokine/receptor complex and interfering with the cytokine's effects.</p><p><a class="drug drug_general" data-topicid="10208" href="/d/drug information/10208.html" rel="external">Tocilizumab</a> is used for rheumatoid arthritis, juvenile idiopathic arthritis and Castleman disease. (See  <a class="medical medical_review" href="/d/html/6400.html" rel="external">"Systemic juvenile idiopathic arthritis: Treatment", section on 'Interleukin 6 inhibitors'</a> and  <a class="medical medical_review" href="/d/html/117312.html" rel="external">"HHV-8-negative/idiopathic multicentric Castleman disease", section on 'IL-6 inhibitors'</a> and  <a class="medical medical_review" href="/d/html/103866.html" rel="external">"Treatment of rheumatoid arthritis in adults resistant to initial biologic DMARD therapy", section on 'IL-6 inhibitor therapies'</a> and  <a class="medical medical_review" href="/d/html/7490.html" rel="external">"Treatment of rheumatoid arthritis in adults resistant to initial conventional synthetic (nonbiologic) DMARD therapy", section on 'Methotrexate plus IL-6 inhibitor/IL-6 inhibitor monotherapy'</a>.)</p><p><a class="drug drug_general" data-topicid="10208" href="/d/drug information/10208.html" rel="external">Tocilizumab</a> has also shown benefit in giant cell arteritis (approved for this indication in the United States and Europe) as well as interstitial lung disease associated with systemic sclerosis (approved in the United States) [<a href="#rid31">31</a>] (see  <a class="medical medical_review" href="/d/html/8240.html" rel="external">"Treatment of giant cell arteritis", section on 'Tocilizumab'</a> and  <a class="medical medical_review" href="/d/html/4375.html" rel="external">"Treatment and prognosis of interstitial lung disease in systemic sclerosis (scleroderma)", section on 'Tocilizumab'</a>). It is also used in patients with COVID-19 and patients with cytokine release syndrome associated with chimeric antigen receptor (CAR)-T cell therapy. (See  <a class="medical medical_review" href="/d/html/127429.html" rel="external">"COVID-19: Management in hospitalized adults", section on 'IL-6 pathway inhibitors (eg, tocilizumab)'</a> and  <a class="medical medical_review" href="/d/html/118012.html" rel="external">"Cytokine release syndrome (CRS)", section on 'CAR-T cell-associated CRS'</a>.)</p><p class="headingAnchor" id="H714776930"><span class="h3">Sarilumab</span><span class="headingEndMark"> — </span>Another human mAb, <a class="drug drug_general" data-topicid="113315" href="/d/drug information/113315.html" rel="external">sarilumab</a>, is a fully human recombinant mAb of the IgG1 subclass that binds to the IL-6R and acts as an IL-6R antagonist. It is directed against both the membrane-bound and soluble IL-6R and is available in the United States and the European Union for the treatment of rheumatoid arthritis. In the United States, sarilumab has also been approved for the treatment of refractory polymyalgia rheumatica [<a href="#rid32">32</a>]. It is administered by subcutaneous injection every two weeks [<a href="#rid33">33-35</a>].</p><p class="headingAnchor" id="H587891650"><span class="h2">IL-17 inhibition</span><span class="headingEndMark"> — </span>IL-17, which is produced by Th17 cells, amplifies production of multiple cytokines and stimulates keratinocytes, synoviocytes, macrophages, fibroblasts, and neutrophils [<a href="#rid36">36</a>]. Antibodies that target the IL-17 pathways have been developed and are marketed for the treatment of several conditions in which the IL-17 pathway has a role, including psoriasis and psoriatic arthritis, spondyloarthritis, and other immune-mediated diseases.</p><p class="headingAnchor" id="H395941591"><span class="h3">Secukinumab</span><span class="headingEndMark"> — </span><a class="drug drug_general" data-topicid="99569" href="/d/drug information/99569.html" rel="external">Secukinumab</a> is a fully human IgG1 kappa mAb against IL-17 [<a href="#rid37">37</a>]. It is commercially available for use in psoriasis, psoriatic arthritis, ankylosing spondylitis, nonradiographic axial spondyloarthritis, hidradenitis suppurativa, and inflammatory bowel disease. It has also been used in uveitis [<a href="#rid37">37</a>]. Its efficacy in rheumatoid arthritis (for which it has not been approved) appears to be modest, and comparatively less than in these other conditions, based upon limited study [<a href="#rid38">38</a>].</p><p><a class="drug drug_general" data-topicid="99569" href="/d/drug information/99569.html" rel="external">Secukinumab</a> is administered by monthly subcutaneous injection after several loading doses [<a href="#rid39">39</a>]. An intravenous form of secukinumab is also available [<a href="#rid40">40</a>].</p><p class="headingAnchor" id="H3870077624"><span class="h3">Ixekizumab</span><span class="headingEndMark"> — </span><a class="drug drug_general" data-topicid="107448" href="/d/drug information/107448.html" rel="external">Ixekizumab</a>, a humanized mAb against IL-17A, has been granted FDA and EMA approval for the treatment of psoriasis and has been effective for psoriatic arthritis as well. It has also been granted EMA approval for psoriatic arthritis.</p><p class="headingAnchor" id="H1468706153"><span class="h3">Bimekizumab</span><span class="headingEndMark"> — </span><a class="drug drug_general" data-topicid="138686" href="/d/drug information/138686.html" rel="external">Bimekizumab</a>, a humanized mAb against IL-17A and IL-17F, has been granted EMA approval for the treatment of plaque psoriasis, psoriatic arthritis, and non-radiographic and radiographic axial spondyloarthritis [<a href="#rid41">41</a>]. Bimekizumab is also approved in Canada and the US for plaque psoriasis [<a href="#rid42">42</a>].</p><p class="headingAnchor" id="H2649539375"><span class="h2">IL-12/23 blockade</span></p><p class="headingAnchor" id="H3132423889"><span class="h3">Ustekinumab</span><span class="headingEndMark"> — </span><a class="drug drug_general" data-topicid="9514" href="/d/drug information/9514.html" rel="external">Ustekinumab</a> is a human IgG1 kappa mAb that binds to the p40 subunit shared by IL-12 and IL-23. It is available for use in the treatment of psoriasis and psoriatic arthritis [<a href="#rid43">43</a>]. It is administered every 12 weeks by subcutaneous injection after several loading doses. </p><p><a class="drug drug_general" data-topicid="9514" href="/d/drug information/9514.html" rel="external">Ustekinumab</a> interferes with the binding of the proinflammatory cytokines IL-12 and IL-23 to their cell surface receptors. Biologic effects of IL-12 and IL-23 include natural killer (NK) cell activation, CD4+ T-cell differentiation and activation. Ustekinumab also interferes with the expression of monocyte chemotactic protein (MCP)-1, TNF-alpha, interferon-inducible protein-10 (IP-10), and IL-8. </p><p><a class="drug drug_general" data-topicid="9514" href="/d/drug information/9514.html" rel="external">Ustekinumab</a> is also approved by the EMA for the treatment of adult patients with moderately to severely active Crohn disease who have had an inadequate response with, lost response to, or were intolerant to either conventional therapy or a TNF-alpha antagonist or have medical contraindications to such therapies [<a href="#rid44">44</a>].</p><p class="headingAnchor" id="H3972927517"><span class="h3">Guselkumab</span><span class="headingEndMark"> — </span><a class="drug drug_general" data-topicid="114007" href="/d/drug information/114007.html" rel="external">Guselkumab</a> is a human IgG1 mAb directed against the p19 subunit of IL-23 and is thus specific for IL-23, not binding to IL-12. It is highly efficacious in psoriasis and also works in psoriatic arthritis. It has been approved for the treatment of moderate to severe plaque psoriasis in adults who are candidates for systemic therapy. It has been approved by the FDA and EMA for use in psoriatic arthritis.</p><p class="headingAnchor" id="H3966064295"><span class="h3">Risankizumab</span><span class="headingEndMark"> — </span><a class="drug drug_general" data-topicid="121112" href="/d/drug information/121112.html" rel="external">Risankizumab</a> is a humanized IgG1 mAb directed against the p19 subunit of IL-23 [<a href="#rid45">45-47</a>]. It was approved by the FDA and EMA for the treatment of moderate to severe plaque psoriasis in adults who are candidates for systemic therapy or phototherapy and subsequently approved for the treatment of psoriatic arthritis. It is administered subcutaneously 4 weeks apart for the first 2 doses, then every 12 weeks, and may be administered alone or in combination with conventional synthetic DMARDs.</p><p class="headingAnchor" id="H25"><span class="h1">COSTIMULATION BLOCKADE</span><span class="headingEndMark"> — </span>A biologic agent, <a class="drug drug_general" data-topicid="8526" href="/d/drug information/8526.html" rel="external">abatacept</a>, that targets a key pathway in T-cell costimulation is available for use in rheumatoid arthritis (and psoriatic arthritis) and is under study in other rheumatic diseases. CD28 and CTLA-4 (CD152) are important in the regulation of T-cell activation and function; they help control some of the cross-talk between T cells, on which they are primarily expressed, and antigen-presenting cells, on which they interact with their ligands, CD80 and CD86 (also termed B7-1 and B7-2) [<a href="#rid48">48</a>]. CD28 binding has been found to decrease the activity of regulatory T cells (T reg) and to increase T effector cell activity, while CTLA-4 may, by contrast, ultimately activate T effector cells without suppressing T reg activity [<a href="#rid49">49</a>]. Thus, targeting of these pathways can impact immune function. (See  <a class="medical medical_review" href="/d/html/7346.html" rel="external">"Transplantation immunobiology", section on 'T cell costimulation'</a>.)</p><p class="headingAnchor" id="H26"><span class="h2">Abatacept</span><span class="headingEndMark"> — </span><a class="drug drug_general" data-topicid="8526" href="/d/drug information/8526.html" rel="external">Abatacept</a> is a soluble fusion protein comprising CTLA-4 and the Fc portion of immunoglobulin G1 (IgG1) (CTLA4-Ig). Abatacept is available for use in the treatment of rheumatoid arthritis, juvenile idiopathic arthritis, and psoriatic arthritis. Abatacept can be administered by either weekly subcutaneous injection or by monthly intravenous infusion following several loading doses. (See  <a class="medical medical_review" href="/d/html/103866.html" rel="external">"Treatment of rheumatoid arthritis in adults resistant to initial biologic DMARD therapy", section on 'Abatacept'</a> and  <a class="medical medical_review" href="/d/html/7490.html" rel="external">"Treatment of rheumatoid arthritis in adults resistant to initial conventional synthetic (nonbiologic) DMARD therapy", section on 'Methotrexate plus abatacept'</a>.)</p><p><a class="drug drug_general" data-topicid="8526" href="/d/drug information/8526.html" rel="external">Abatacept</a> prevents CD28 from binding to its counter-receptor, CD80/CD86, due to its higher affinity for CD80/CD86. This prevents the suppression of T reg activity and prevents increased T effector cell activity [<a href="#rid49">49</a>]. Administration of CTLA4-Ig or successful transfer of its gene also prevents or ameliorates collagen-induced arthritis in mice, and it is beneficial in transplantation models [<a href="#rid50">50,51</a>].</p><p class="headingAnchor" id="H27"><span class="h1">B-CELL DEPLETION AND INHIBITION</span><span class="headingEndMark"> — </span>Biologic agents that can deplete B cells (eg, <a class="drug drug_general" data-topicid="9616" href="/d/drug information/9616.html" rel="external">rituximab</a>) or inhibit factors that activate B cells (<a class="drug drug_general" data-topicid="16479" href="/d/drug information/16479.html" rel="external">belimumab</a>) are used for the treatment of a range of rheumatic and other diseases. In addition to their central role in antibody production, B cells present antigen to T cells, activate T cells, and promote the production of proinflammatory cytokines, including interleukin (IL) 1, IL-4, IL-6, IL-8, IL-10, and IL-12; tumor necrosis factor (TNF)-alpha; vascular endothelial growth factor (VEGF); monocyte chemotactic protein (MCP); and macrophage migration inhibitory factor (MIF) [<a href="#rid52">52</a>]. (See  <a class="medical medical_review" href="/d/html/13933.html" rel="external">"Normal B and T lymphocyte development"</a>.)</p><p class="headingAnchor" id="H28"><span class="h2">Rituximab</span><span class="headingEndMark"> — </span><a class="drug drug_general" data-topicid="9616" href="/d/drug information/9616.html" rel="external">Rituximab</a>, a chimeric immunoglobulin G1 (IgG1) monoclonal antibody (mAb), is used to treat lymphoproliferative disorders and several rheumatic diseases. It eliminates CD20-positive B cells, induces complement mediated cytotoxicity, and stimulates apoptosis but has little and/or nonspecific effects on existing protective autoantibody titers, with a profound negative effect on de novo antibody formation (eg, following COVID-19 vaccination). It is probable that some combination of these effects accounts for its activity in autoimmune disease [<a href="#rid53">53</a>]. It is usually administered as a short series of typically two or four intravenous infusions every four to six months or at longer intervals as needed. (See  <a class="medical medical_review" href="/d/html/7501.html" rel="external">"Rituximab: Principles of use and adverse effects in rheumatoid arthritis"</a> and  <a class="medical medical_review" href="/d/html/4729.html" rel="external">"Initial treatment of advanced stage diffuse large B cell lymphoma", section on 'Incorporation of rituximab'</a>.)</p><p>In addition to treatment of non-Hodgkin lymphoma and chronic lymphocytic leukemia, <a class="drug drug_general" data-topicid="9616" href="/d/drug information/9616.html" rel="external">rituximab</a> is indicated for treating rheumatoid arthritis and granulomatosis with polyangiitis and microscopic polyangiitis. It has also been used in systemic lupus erythematosus, systemic sclerosis, and other forms of vasculitis as well as myositis, although it is not formally approved by regulatory agencies for any of these other conditions. (See  <a class="medical medical_review" href="/d/html/3105.html" rel="external">"Granulomatosis with polyangiitis and microscopic polyangiitis: Induction and maintenance therapy"</a>.)</p><p>Implications of <a class="drug drug_general" data-topicid="9616" href="/d/drug information/9616.html" rel="external">rituximab</a> use in patients during the COVID-19 pandemic are described separately. (See  <a class="medical medical_review" href="/d/html/127933.html" rel="external">"COVID-19: Care of adult patients with systemic rheumatic disease"</a>.)</p><p class="headingAnchor" id="H3932672969"><span class="h2">Belimumab</span><span class="headingEndMark"> — </span><a class="drug drug_general" data-topicid="16479" href="/d/drug information/16479.html" rel="external">Belimumab</a> is an anti-B lymphocyte stimulator (BLyS) mAb which binds to soluble BLyS, preventing its binding and stimulation of B cells [<a href="#rid52">52</a>]. It is available for use for the treatment of systemic lupus erythematosus and is being studied in other conditions, such as Sjögren's disease. Belimumab is administered by intravenous infusion every four weeks after therapy is initiated with several more frequent loading doses. It is also available for subcutaneous injections. (See  <a class="medical medical_review" href="/d/html/4675.html" rel="external">"Overview of the management and prognosis of systemic lupus erythematosus in adults"</a>.)</p><p class="headingAnchor" id="H1347284582"><span class="h2">Anifrolumab</span><span class="headingEndMark"> — </span><a class="drug drug_general" data-topicid="132266" href="/d/drug information/132266.html" rel="external">Anifrolumab</a> is a first-in-class global type 1 interferon inhibitor approved by the FDA for systemic lupus erythematosus in addition to standard of care [<a href="#rid54">54</a>].</p><p class="headingAnchor" id="H3013948372"><span class="h1">BIOSIMILARS FOR BIOLOGIC AGENTS</span></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Definitions</strong> – The World Health Organization (WHO) defines a biosimilar as a "biotherapeutic product which is similar in terms of quality, safety, and efficacy to an already licensed reference biotherapeutic product" [<a href="#rid55">55</a>]. "Similarity" is defined as the "absence of a relevant difference in the parameter of interest."</p><p></p><p class="bulletIndent1">A biosimilar (unlike a "biomimic" or "biocopy," which are medications marketed in some countries) has the same primary amino acid sequence as the reference product and has undergone rigorous analytic and clinical testing in comparison with its reference product [<a href="#rid56">56</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Availability</strong> – Multiple biosimilar agents have been approved by regulatory agencies in several countries and regions, and their availability is growing. Copies of biologic agents, including several of the tumor necrosis factor (TNF) inhibitors, <a class="drug drug_general" data-topicid="9616" href="/d/drug information/9616.html" rel="external">rituximab</a>, and other therapeutic molecules, have been marketed and are under development for use in the rheumatic diseases. The availability of each of these agents and approved indications for their use will depend upon regulatory requirements in different regions and local patent laws and patent expiration dates [<a href="#rid57">57-59</a>].</p><p></p><p class="bulletIndent1">Commercially available products that have received regulatory designation as biosimilar (eg, <a class="drug drug_general" data-topicid="8984" href="/d/drug information/8984.html" rel="external">infliximab</a>, <a class="drug drug_general" data-topicid="8925" href="/d/drug information/8925.html" rel="external">etanercept</a>, <a class="drug drug_general" data-topicid="8583" href="/d/drug information/8583.html" rel="external">adalimumab</a>, and <a class="drug drug_general" data-topicid="9616" href="/d/drug information/9616.html" rel="external">rituximab</a>) in the United States, Canada, and some other countries are described in the drug information monograph (Lexicomp) included within UpToDate for the legacy (originator) biologic agent [<a href="#rid57">57,60-64</a>]. (See  <a class="drug drug_general" href="/d/drug information/8984.html" rel="external">"Infliximab (including biosimilars): Drug information"</a> and  <a class="drug drug_general" href="/d/drug information/8925.html" rel="external">"Etanercept (including biosimilars available in Canada): Drug information"</a> and  <a class="drug drug_general" href="/d/drug information/8583.html" rel="external">"Adalimumab (including biosimilars): Drug information"</a>.)</p><p></p><p class="bulletIndent1">An updated list of <a class="external" href="/external-redirect?target_url=https%3A%2F%2Fwww.fda.gov%2Fmedia%2F105605%2Fdownload&amp;token=8RYIFfyLhIBYEqeX7m6uPH%2BjczMgtOIy84OL27tgmAw%2B8lRUYBtgtyYrZHI4OlTlixLwNmZucsDDtCWJksRURg%3D%3D&amp;TOPIC_ID=7966" target="_blank">biologic products and biosimilars</a> approved by the US Food and Drug Administration (FDA) is available through the FDA Center for Drug Evaluation and Research [<a href="#rid65">65</a>], and updated information regarding biosimilars approved by the European Medicines Agency (EMA) is also available [<a href="#rid66">66,67</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Equivalence with bio-originators</strong> – The American College of Rheumatology (ACR) has issued a "white paper" that recommends the use of biosimilars for patients with rheumatic diseases [<a href="#rid68">68</a>]. The ACR report highlights the scientific rigor with which the FDA and other regulatory agencies outside of the United States have evaluated these agents, including the process of extrapolation of indications.</p><p></p><p>The data supporting the use of biosimilar TNF-alpha inhibitors are particularly robust:</p><p class="bulletIndent2"><span class="glyph">•</span>A 2016 systematic review described the results of 19 observational studies and clinical trials that compared biosimilar TNF-alpha inhibitors with their reference biologic products, including <a class="drug drug_general" data-topicid="8984" href="/d/drug information/8984.html" rel="external">infliximab</a>, <a class="drug drug_general" data-topicid="8925" href="/d/drug information/8925.html" rel="external">etanercept</a>, and <a class="drug drug_general" data-topicid="8583" href="/d/drug information/8583.html" rel="external">adalimumab</a> [<a href="#rid69">69</a>]. The studies included patients with rheumatoid arthritis, ankylosing spondylitis, and inflammatory bowel disease. Pharmacokinetic measurements for the respective biosimilar drugs and their reference products were within defined equivalence margins, and similar clinical responses and adverse events were found for biosimilars their reference drugs. Two studies documented immunologic cross-reactivity between products, and similar efficacy and safety were observed in four cohort studies in which patients were switched from the reference product to a biosimilar medication.</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>A subsequent meta-analysis described the results of 25 clinical trials of 10,642 patients with rheumatoid arthritis that compared biosimilar TNF-alpha inhibitors with their reference biologic products, including <a class="drug drug_general" data-topicid="8984" href="/d/drug information/8984.html" rel="external">infliximab</a>, <a class="drug drug_general" data-topicid="8925" href="/d/drug information/8925.html" rel="external">etanercept</a>, and <a class="drug drug_general" data-topicid="8583" href="/d/drug information/8583.html" rel="external">adalimumab</a> [<a href="#rid70">70</a>]. Biosimilars were equivalent to reference biologics in terms of disease activity (ACR 20 response; relative risk [RR] 1.01) and patient function (Health Assessment Questionnaire Disability Index [HAQ-DI] scores; standardized mean difference -0.04).</p><p></p><p class="headingAnchor" id="H4291213193"><span class="h1">SOCIETY GUIDELINE LINKS</span><span class="headingEndMark"> — </span>Links to society and government-sponsored guidelines from selected countries and regions around the world are provided separately. (See  <a class="medical medical_society_guidelines" href="/d/html/120032.html" rel="external">"Society guideline links: Side effects of anti-inflammatory and anti-rheumatic drugs"</a>.)</p><p class="headingAnchor" id="H29"><span class="h1">SUMMARY</span></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Biologic targeting for rheumatologic disease treatment</strong> – The major biologic approaches to treatment of the rheumatologic diseases include agents that (see <a class="local">'Anticytokine approaches'</a> above):</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Interfere with cytokine function</p><p class="bulletIndent2"><span class="glyph">•</span>Interfere with interferon function</p><p class="bulletIndent2"><span class="glyph">•</span>Inhibit the "second signal" required for T-cell activation</p><p class="bulletIndent2"><span class="glyph">•</span>Deplete B cells</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Biologic therapeutic agents for rheumatologic disease</strong> – The following biologic treatment strategies are employed in rheumatic disease:</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Tumor necrosis factor (TNF) inhibition (see <a class="local">'TNF inhibition'</a> above)</p><p class="bulletIndent2"><span class="glyph">•</span>Interleukin (IL) 1 inhibition (see <a class="local">'IL-1 inhibition'</a> above)</p><p class="bulletIndent2"><span class="glyph">•</span>IL-6 inhibition (see <a class="local">'IL-6 inhibition'</a> above)</p><p class="bulletIndent2"><span class="glyph">•</span>IL-17 inhibition (see <a class="local">'IL-17 inhibition'</a> above)</p><p class="bulletIndent2"><span class="glyph">•</span>IL-12/23 inhibition (see <a class="local">'IL-12/23 blockade'</a> above)</p><p class="bulletIndent2"><span class="glyph">•</span>Costimulation blockade (see <a class="local">'Costimulation blockade'</a> above)</p><p class="bulletIndent2"><span class="glyph">•</span>B-cell depletion and inhibition of B-cell activation (see <a class="local">'B-cell depletion and inhibition'</a> above)</p><p class="bulletIndent2"><span class="glyph">•</span>Interferon type 1 inhibition</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Biosimilars</strong> – Copies of biologic agents that are no longer under patent protection are becoming available for use in multiple countries. These medications have the same amino acid sequences as the original reference molecules, and the regulatory regimens require these biosimilar agents to be highly similar in terms of quality, safety, and efficacy to the already-licensed reference biotherapeutic product. (See <a class="local">'Biosimilars for biologic agents'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Janus kinase inhibitors</strong> – <a class="drug drug_general" data-topicid="87040" href="/d/drug information/87040.html" rel="external">Tofacitinib</a>, <a class="drug drug_general" data-topicid="118052" href="/d/drug information/118052.html" rel="external">baricitinib</a>, <a class="drug drug_general" data-topicid="122341" href="/d/drug information/122341.html" rel="external">upadacitinib</a>, peficitinib, and filgotinib are orally administered, highly targeted, small molecule pharmaceutical agents that inhibit Janus kinases (JAK), which are cytoplasmic protein tyrosine kinases that mediate signaling from an array of multiple cytokine receptors to the nucleus. Their therapeutic benefits and adverse effects in rheumatic diseases are generally similar to the biologic agents. (See  <a class="medical medical_review" href="/d/html/130611.html" rel="external">"Overview of the Janus kinase inhibitors for rheumatologic and other inflammatory disorders"</a>.)</p><p></p><p class="headingAnchor" id="H3188082492"><span class="h1">ACKNOWLEDGMENT</span><span class="headingEndMark"> — </span>The editorial staff at UpToDate would like to acknowledge John H Stone, MD, MPH, who contributed to an earlier version of this topic review.</p></div><div class="headingAnchor" id="references"><ol id="reference"><li><a class="nounderline abstract_t">Mosmann TR, Moore KW. The role of IL-10 in crossregulation of TH1 and TH2 responses. Immunol Today 1991; 12:A49.</a></li><li><a class="nounderline abstract_t">Zhu J, Yamane H, Cote-Sierra J, et al. GATA-3 promotes Th2 responses through three different mechanisms: induction of Th2 cytokine production, selective growth of Th2 cells and inhibition of Th1 cell-specific factors. Cell Res 2006; 16:3.</a></li><li><a class="nounderline abstract_t">Bettelli E, Carrier Y, Gao W, et al. Reciprocal developmental pathways for the generation of pathogenic effector TH17 and regulatory T cells. Nature 2006; 441:235.</a></li><li><a class="nounderline abstract_t">Bacchetta R, Gambineri E, Roncarolo MG. Role of regulatory T cells and FOXP3 in human diseases. J Allergy Clin Immunol 2007; 120:227.</a></li><li><a class="nounderline abstract_t">Koenders MI, Joosten LA, van den Berg WB. Potential new targets in arthritis therapy: interleukin (IL)-17 and its relation to tumour necrosis factor and IL-1 in experimental arthritis. Ann Rheum Dis 2006; 65 Suppl 3:iii29.</a></li><li><a class="nounderline abstract_t">Lamberg L. A host of novel agents for treating psoriasis, psoriatic arthritis stir interest. JAMA 2003; 289:2779.</a></li><li><a class="nounderline abstract_t">Balocco R, De Sousa Guimaraes Koch S, Thorpe R, et al. New INN nomenclature for monoclonal antibodies. Lancet 2022; 399:24.</a></li><li><a class="nounderline abstract_t">Heaney ML, Golde DW. Soluble cytokine receptors. Blood 1996; 87:847.</a></li><li><a class="nounderline abstract_t">Bendtzen K, Hansen MB, Ross C, et al. Cytokines and autoantibodies to cytokines. Stem Cells 1995; 13:206.</a></li><li><a class="nounderline abstract_t">Arend WP. Interleukin 1 receptor antagonist. A new member of the interleukin 1 family. J Clin Invest 1991; 88:1445.</a></li><li><a class="nounderline abstract_t">Aaltonen KJ, Virkki LM, Malmivaara A, et al. Systematic review and meta-analysis of the efficacy and safety of existing TNF blocking agents in treatment of rheumatoid arthritis. PLoS One 2012; 7:e30275.</a></li><li><a class="nounderline abstract_t">Dörner T, Kay J. Biosimilars in rheumatology: current perspectives and lessons learnt. Nat Rev Rheumatol 2015; 11:713.</a></li><li class="breakAll">Remsima. European Medicines Agency (EMA) Summary of product characteristics. Last updated January 12, 2020. European Medicines Agency. (Available online at www.ema.europa.eu/en/documents/product-information/remsima-epar-product-information_en.pdf).</li><li class="breakAll">Infliximab-dyyb injection. United States prescribing information. Revised October 2023. US National Library of Medicine. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/761358s000lbl.pdf (Accessed on January 10, 2024).</li><li><a class="nounderline abstract_t">Goss SL, Klein CE, Jin Z, et al. Methotrexate Dose in Patients With Early Rheumatoid Arthritis Impacts Methotrexate Polyglutamate Pharmacokinetics, Adalimumab Pharmacokinetics, and Efficacy: Pharmacokinetic and Exposure-response Analysis of the CONCERTO Trial. Clin Ther 2018; 40:309.</a></li><li><a class="nounderline abstract_t">Bellinvia S, Cummings JRF, Ardern-Jones MR, Edwards CJ. Adalimumab Biosimilars in Europe: An Overview of the Clinical Evidence. BioDrugs 2019; 33:241.</a></li><li class="breakAll">HIGHLIGHTS OF PRESCRIBING INFORMATION for YUSIMRY (adalimumab-aqvh) injection, for subcutaneous use https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/761216s000lbl.pdf (Accessed on February 23, 2022).</li><li><a class="nounderline abstract_t">Mariette X, Förger F, Abraham B, et al. Lack of placental transfer of certolizumab pegol during pregnancy: results from CRIB, a prospective, postmarketing, pharmacokinetic study. Ann Rheum Dis 2018; 77:228.</a></li><li><a class="nounderline abstract_t">Clowse ME, Förger F, Hwang C, et al. Minimal to no transfer of certolizumab pegol into breast milk: results from CRADLE, a prospective, postmarketing, multicentre, pharmacokinetic study. Ann Rheum Dis 2017; 76:1890.</a></li><li><a class="nounderline abstract_t">Donahue KE, Gartlehner G, Jonas DE, et al. Systematic review: comparative effectiveness and harms of disease-modifying medications for rheumatoid arthritis. Ann Intern Med 2008; 148:124.</a></li><li><a class="nounderline abstract_t">Mertens M, Singh JA. Anakinra for rheumatoid arthritis. Cochrane Database Syst Rev 2009; :CD005121.</a></li><li><a class="nounderline abstract_t">Weisman MH. What are the risks of biologic therapy in rheumatoid arthritis? An update on safety. J Rheumatol Suppl 2002; 65:33.</a></li><li><a class="nounderline abstract_t">Genovese MC, Cohen S, Moreland L, et al. Combination therapy with etanercept and anakinra in the treatment of patients with rheumatoid arthritis who have been treated unsuccessfully with methotrexate. Arthritis Rheum 2004; 50:1412.</a></li><li class="breakAll">http://www.ema.europa.eu/ema/index.jsp?curl=pages/medicines/human/medicines/000363/human_med_000874.jsp&amp;mid=WC0b01ac058001d124 (Accessed on July 10, 2018).</li><li><a class="nounderline abstract_t">Schlesinger N, Alten RE, Bardin T, et al. Canakinumab for acute gouty arthritis in patients with limited treatment options: results from two randomised, multicentre, active-controlled, double-blind trials and their initial extensions. Ann Rheum Dis 2012; 71:1839.</a></li><li class="breakAll">Canakinumab. European Medicines Agency (EMA) summary of product characteristics. Last updated August 25, 2023. European Medicines Agency. https://www.ema.europa.eu/en/medicines/human/EPAR/ilaris (Accessed on July 10, 2018).</li><li class="breakAll">Canakinumab injection. US Food and Drug Administration (FDA) approved product information. Revised August 2023. US Food and Drug Administration. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/125319s107lbl.pdf (Accessed on September 12, 2023).</li><li><a class="nounderline abstract_t">Akira S, Taga T, Kishimoto T. Interleukin-6 in biology and medicine. Adv Immunol 1993; 54:1.</a></li><li><a class="nounderline abstract_t">Okuda Y. Review of tocilizumab in the treatment of rheumatoid arthritis. Biologics 2008; 2:75.</a></li><li><a class="nounderline abstract_t">Hirano T. Interleukin 6 and its receptor: ten years later. Int Rev Immunol 1998; 16:249.</a></li><li class="breakAll">http://www.ema.europa.eu/ema/index.jsp?curl=pages/medicines/human/medicines/000955/human_med_001042.jsp&amp;mid=WC0b01ac058001d124 (Accessed on July 10, 2018).</li><li class="breakAll">KEVZARA (sarilumab) injection, for subcutaneous use. US Food and Drug Administration (FDA) approved product information. Revised February 2023. US Food and Drug Administration. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/761037s013lbl.pdf (Accessed on April 10, 2023).</li><li><a class="nounderline abstract_t">Genovese MC, Fleischmann R, Kivitz AJ, et al. Sarilumab Plus Methotrexate in Patients With Active Rheumatoid Arthritis and Inadequate Response to Methotrexate: Results of a Phase III Study. Arthritis Rheumatol 2015; 67:1424.</a></li><li><a class="nounderline abstract_t">Burmester GR, Lin Y, Patel R, et al. Efficacy and safety of sarilumab monotherapy versus adalimumab monotherapy for the treatment of patients with active rheumatoid arthritis (MONARCH): a randomised, double-blind, parallel-group phase III trial. Ann Rheum Dis 2017; 76:840.</a></li><li><a class="nounderline abstract_t">Fleischmann R, van Adelsberg J, Lin Y, et al. Sarilumab and Nonbiologic Disease-Modifying Antirheumatic Drugs in Patients With Active Rheumatoid Arthritis and Inadequate Response or Intolerance to Tumor Necrosis Factor Inhibitors. Arthritis Rheumatol 2017; 69:277.</a></li><li><a class="nounderline abstract_t">Waite JC, Skokos D. Th17 response and inflammatory autoimmune diseases. Int J Inflam 2012; 2012:819467.</a></li><li><a class="nounderline abstract_t">Patel DD, Lee DM, Kolbinger F, Antoni C. Effect of IL-17A blockade with secukinumab in autoimmune diseases. Ann Rheum Dis 2013; 72 Suppl 2:ii116.</a></li><li><a class="nounderline abstract_t">Genovese MC, Durez P, Richards HB, et al. Efficacy and safety of secukinumab in patients with rheumatoid arthritis: a phase II, dose-finding, double-blind, randomised, placebo controlled study. Ann Rheum Dis 2013; 72:863.</a></li><li><a class="nounderline abstract_t">Ramiro S, Smolen JS, Landewé R, et al. Pharmacological treatment of psoriatic arthritis: a systematic literature review for the 2015 update of the EULAR recommendations for the management of psoriatic arthritis. Ann Rheum Dis 2016; 75:490.</a></li><li class="breakAll">Secukinumab injection, for subcutaneous or intravenous use. United States prescribing information. Revised October 2023. US National Library of Medicine. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/125504s073lbl.pdf (Accessed on January 10, 2024).</li><li class="breakAll">Bimzelx. European Medicines Agency (EMA) summary of product characteristics. European Medicines Agency. https://www.ema.europa.eu/en/documents/product-information/bimzelx-epar-product-information_en.pdf (Accessed on June 16, 2023).</li><li class="breakAll">Biimekizumab injection. Health Canada-approved product monograph. Revised May 30, 2023. https://pdf.hres.ca/dpd_pm/00071095.PDF (Accessed on September 12, 2023).</li><li><a class="nounderline abstract_t">Kavanaugh A, Ritchlin C, Rahman P, et al. Ustekinumab, an anti-IL-12/23 p40 monoclonal antibody, inhibits radiographic progression in patients with active psoriatic arthritis: results of an integrated analysis of radiographic data from the phase 3, multicentre, randomised, double-blind, placebo-controlled PSUMMIT-1 and PSUMMIT-2 trials. Ann Rheum Dis 2014; 73:1000.</a></li><li class="breakAll">http://www.ema.europa.eu/ema/index.jsp?curl=pages/medicines/human/medicines/000958/human_med_001065.jsp&amp;mid=WC0b01ac058001d124 (Accessed on July 10, 2018).</li><li><a class="nounderline abstract_t">Krueger JG, Ferris LK, Menter A, et al. Anti-IL-23A mAb BI 655066 for treatment of moderate-to-severe psoriasis: Safety, efficacy, pharmacokinetics, and biomarker results of a single-rising-dose, randomized, double-blind, placebo-controlled trial. J Allergy Clin Immunol 2015; 136:116.</a></li><li><a class="nounderline abstract_t">Kristensen LE, Keiserman M, Papp K, et al. Efficacy and safety of risankizumab for active psoriatic arthritis: 24-week results from the randomised, double-blind, phase 3 KEEPsAKE 1 trial. Ann Rheum Dis 2022; 81:225.</a></li><li><a class="nounderline abstract_t">Östör A, Van den Bosch F, Papp K, et al. Efficacy and safety of risankizumab for active psoriatic arthritis: 24-week results from the randomised, double-blind, phase 3 KEEPsAKE 2 trial. Ann Rheum Dis 2022; 81:351.</a></li><li><a class="nounderline abstract_t">Lenschow DJ, Walunas TL, Bluestone JA. CD28/B7 system of T cell costimulation. Annu Rev Immunol 1996; 14:233.</a></li><li><a class="nounderline abstract_t">Dilek N, Poirier N, Hulin P, et al. Targeting CD28, CTLA-4 and PD-L1 costimulation differentially controls immune synapses and function of human regulatory and conventional T-cells. PLoS One 2013; 8:e83139.</a></li><li><a class="nounderline abstract_t">Larsen CP, Elwood ET, Alexander DZ, et al. Long-term acceptance of skin and cardiac allografts after blocking CD40 and CD28 pathways. Nature 1996; 381:434.</a></li><li><a class="nounderline abstract_t">Quattrocchi E, Dallman MJ, Feldmann M. Adenovirus-mediated gene transfer of CTLA-4Ig fusion protein in the suppression of experimental autoimmune arthritis. Arthritis Rheum 2000; 43:1688.</a></li><li><a class="nounderline abstract_t">Engel P, Gómez-Puerta JA, Ramos-Casals M, et al. Therapeutic targeting of B cells for rheumatic autoimmune diseases. Pharmacol Rev 2011; 63:127.</a></li><li><a class="nounderline abstract_t">Pateinakis P, Pyrpasopoulou A. CD20+ B cell depletion in systemic autoimmune diseases: common mechanism of inhibition or disease-specific effect on humoral immunity? Biomed Res Int 2014; 2014:973609.</a></li><li><a class="nounderline abstract_t">Tanaka Y, Tummala R. Anifrolumab, a monoclonal antibody to the type I interferon receptor subunit 1, for the treatment of systemic lupus erythematosus: an overview from clinical trials. Mod Rheumatol 2021; 31:1.</a></li><li class="breakAll">World Health Organization. Expert Committee on Biological Standardization.  Guidelines on evaluation of similar biotherapeutic products. Geneva, 2009. http://www.who.int/biologicals/areas/biological_ (Accessed on September 28, 2013).</li><li><a class="nounderline abstract_t">Kay J. Editorial: Biosimilars: New or Déjà Vu? Arthritis Rheumatol 2016; 68:1049.</a></li><li><a class="nounderline abstract_t">Dörner T, Strand V, Cornes P, et al. The changing landscape of biosimilars in rheumatology. Ann Rheum Dis 2016; 75:974.</a></li><li><a class="nounderline abstract_t">Gherghescu I, Delgado-Charro MB. The Biosimilar Landscape: An Overview of Regulatory Approvals by the EMA and FDA. Pharmaceutics 2020; 13.</a></li><li><a class="nounderline abstract_t">Kay J, Smolen JS. Biosimilars to treat inflammatory arthritis: the challenge of proving identity. Ann Rheum Dis 2013; 72:1589.</a></li><li><a class="nounderline abstract_t">Yoo DH, Hrycaj P, Miranda P, et al. A randomised, double-blind, parallel-group study to demonstrate equivalence in efficacy and safety of CT-P13 compared with innovator infliximab when coadministered with methotrexate in patients with active rheumatoid arthritis: the PLANETRA study. Ann Rheum Dis 2013; 72:1613.</a></li><li><a class="nounderline abstract_t">Park W, Hrycaj P, Jeka S, et al. A randomised, double-blind, multicentre, parallel-group, prospective study comparing the pharmacokinetics, safety, and efficacy of CT-P13 and innovator infliximab in patients with ankylosing spondylitis: the PLANETAS study. Ann Rheum Dis 2013; 72:1605.</a></li><li><a class="nounderline abstract_t">Kim SC, Choi NK, Lee J, et al. Brief Report: Utilization of the First Biosimilar Infliximab Since Its Approval in South Korea. Arthritis Rheumatol 2016; 68:1076.</a></li><li class="breakAll">US Food and Drug Administration. FDA news release: FDA approves Inflectra, a biosimilar to Remicade. April 2016. https://www.fda.gov/news-events/press-announcements/fda-approves-inflectra-biosimilar-remicade (Accessed on June 26, 2023).</li><li><a class="nounderline abstract_t">Emery P, Vencovský J, Sylwestrzak A, et al. A phase III randomised, double-blind, parallel-group study comparing SB4 with etanercept reference product in patients with active rheumatoid arthritis despite methotrexate therapy. Ann Rheum Dis 2017; 76:51.</a></li><li class="breakAll">US Food and Drug Administration. Purple Book: Lists of licensed biological products with reference product exclusivity and biosimilarity or interchangeability evaluations. https://www.fda.gov/Drugs/DevelopmentApprovalProcess/HowDrugsareDevelopedandApproved/ApprovalApplications/TherapeuticBiologicApplications/Biosimilars/ucm411418.htm (Accessed on April 06, 2018).</li><li class="breakAll">European Medicines Agency. Biosimilars in the EU. https://www.ema.europa.eu/en/documents/leaflet/biosimilars-eu-information-guide-healthcare-professionals_en.pdf (Accessed on January 14, 2022).</li><li class="breakAll">Generic and Biosimilars Initiative. Biosimilars approved in Europe. https://gabionline.net/biosimilars/general/biosimilars-approved-in-europe (Accessed on January 14, 2022).</li><li><a class="nounderline abstract_t">Bridges SL Jr, White DW, Worthing AB, et al. The Science Behind Biosimilars: Entering a New Era of Biologic Therapy. Arthritis Rheumatol 2018; 70:334.</a></li><li><a class="nounderline abstract_t">Chingcuanco F, Segal JB, Kim SC, Alexander GC. Bioequivalence of Biosimilar Tumor Necrosis Factor-α Inhibitors Compared With Their Reference Biologics: A Systematic Review. Ann Intern Med 2016; 165:565.</a></li><li><a class="nounderline abstract_t">Ascef BO, Almeida MO, Medeiros-Ribeiro AC, et al. Therapeutic Equivalence of Biosimilar and Reference Biologic Drugs in Rheumatoid Arthritis: A Systematic Review and Meta-analysis. JAMA Netw Open 2023; 6:e2315872.</a></li></ol></div><div id="topicVersionRevision">Topic 7966 Version 36.0</div></div>
<div class="row">
<div class="col-12">
<h4 style="text-align: center;padding: 20px;color: cadetblue;">References</h4>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1648926" id="rid0" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>1 : The role of IL-10 in crossregulation of TH1 and TH2 responses.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16467870" id="rid1" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>2 : GATA-3 promotes Th2 responses through three different mechanisms: induction of Th2 cytokine production, selective growth of Th2 cells and inhibition of Th1 cell-specific factors.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16648838" id="rid2" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>3 : Reciprocal developmental pathways for the generation of pathogenic effector TH17 and regulatory T cells.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17666212" id="rid3" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>4 : Role of regulatory T cells and FOXP3 in human diseases.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17038468" id="rid4" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>5 : Potential new targets in arthritis therapy: interleukin (IL)-17 and its relation to tumour necrosis factor and IL-1 in experimental arthritis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12783895" id="rid5" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>6 : A host of novel agents for treating psoriasis, psoriatic arthritis stir interest.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/34973717" id="rid6" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>7 : New INN nomenclature for monoclonal antibodies.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8562952" id="rid7" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>8 : Soluble cytokine receptors.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7613489" id="rid8" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>9 : Cytokines and autoantibodies to cytokines.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1834696" id="rid9" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>10 : Interleukin 1 receptor antagonist. A new member of the interleukin 1 family.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22272322" id="rid10" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>11 : Systematic review and meta-analysis of the efficacy and safety of existing TNF blocking agents in treatment of rheumatoid arthritis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26282080" id="rid11" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>12 : Biosimilars in rheumatology: current perspectives and lessons learnt.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26282080" id="rid12" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>13 : Biosimilars in rheumatology: current perspectives and lessons learnt.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26282080" id="rid13" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>14 : Biosimilars in rheumatology: current perspectives and lessons learnt.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29402521" id="rid14" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>15 : Methotrexate Dose in Patients With Early Rheumatoid Arthritis Impacts Methotrexate Polyglutamate Pharmacokinetics, Adalimumab Pharmacokinetics, and Efficacy: Pharmacokinetic and Exposure-response Analysis of the CONCERTO Trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31111422" id="rid15" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>16 : Adalimumab Biosimilars in Europe: An Overview of the Clinical Evidence.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31111422" id="rid16" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>17 : Adalimumab Biosimilars in Europe: An Overview of the Clinical Evidence.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29030361" id="rid17" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>18 : Lack of placental transfer of certolizumab pegol during pregnancy: results from CRIB, a prospective, postmarketing, pharmacokinetic study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28814432" id="rid18" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>19 : Minimal to no transfer of certolizumab pegol into breast milk: results from CRADLE, a prospective, postmarketing, multicentre, pharmacokinetic study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18025440" id="rid19" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>20 : Systematic review: comparative effectiveness and harms of disease-modifying medications for rheumatoid arthritis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19160248" id="rid20" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>21 : Anakinra for rheumatoid arthritis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12236621" id="rid21" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>22 : What are the risks of biologic therapy in rheumatoid arthritis? An update on safety.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15146410" id="rid22" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>23 : Combination therapy with etanercept and anakinra in the treatment of patients with rheumatoid arthritis who have been treated unsuccessfully with methotrexate.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15146410" id="rid23" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>24 : Combination therapy with etanercept and anakinra in the treatment of patients with rheumatoid arthritis who have been treated unsuccessfully with methotrexate.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22586173" id="rid24" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>25 : Canakinumab for acute gouty arthritis in patients with limited treatment options: results from two randomised, multicentre, active-controlled, double-blind trials and their initial extensions.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22586173" id="rid25" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>26 : Canakinumab for acute gouty arthritis in patients with limited treatment options: results from two randomised, multicentre, active-controlled, double-blind trials and their initial extensions.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22586173" id="rid26" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>27 : Canakinumab for acute gouty arthritis in patients with limited treatment options: results from two randomised, multicentre, active-controlled, double-blind trials and their initial extensions.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8379461" id="rid27" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>28 : Interleukin-6 in biology and medicine.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19707430" id="rid28" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>29 : Review of tocilizumab in the treatment of rheumatoid arthritis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9505191" id="rid29" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>30 : Interleukin 6 and its receptor: ten years later.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9505191" id="rid30" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>31 : Interleukin 6 and its receptor: ten years later.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9505191" id="rid31" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>32 : Interleukin 6 and its receptor: ten years later.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25733246" id="rid32" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>33 : Sarilumab Plus Methotrexate in Patients With Active Rheumatoid Arthritis and Inadequate Response to Methotrexate: Results of a Phase III Study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27856432" id="rid33" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>34 : Efficacy and safety of sarilumab monotherapy versus adalimumab monotherapy for the treatment of patients with active rheumatoid arthritis (MONARCH): a randomised, double-blind, parallel-group phase III trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27860410" id="rid34" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>35 : Sarilumab and Nonbiologic Disease-Modifying Antirheumatic Drugs in Patients With Active Rheumatoid Arthritis and Inadequate Response or Intolerance to Tumor Necrosis Factor Inhibitors.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22229105" id="rid35" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>36 : Th17 response and inflammatory autoimmune diseases.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23253932" id="rid36" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>37 : Effect of IL-17A blockade with secukinumab in autoimmune diseases.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22730366" id="rid37" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>38 : Efficacy and safety of secukinumab in patients with rheumatoid arthritis: a phase II, dose-finding, double-blind, randomised, placebo controlled study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26660203" id="rid38" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>39 : Pharmacological treatment of psoriatic arthritis: a systematic literature review for the 2015 update of the EULAR recommendations for the management of psoriatic arthritis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26660203" id="rid39" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>40 : Pharmacological treatment of psoriatic arthritis: a systematic literature review for the 2015 update of the EULAR recommendations for the management of psoriatic arthritis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26660203" id="rid40" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>41 : Pharmacological treatment of psoriatic arthritis: a systematic literature review for the 2015 update of the EULAR recommendations for the management of psoriatic arthritis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26660203" id="rid41" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>42 : Pharmacological treatment of psoriatic arthritis: a systematic literature review for the 2015 update of the EULAR recommendations for the management of psoriatic arthritis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24553909" id="rid42" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>43 : Ustekinumab, an anti-IL-12/23 p40 monoclonal antibody, inhibits radiographic progression in patients with active psoriatic arthritis: results of an integrated analysis of radiographic data from the phase 3, multicentre, randomised, double-blind, placebo-controlled PSUMMIT-1 and PSUMMIT-2 trials.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24553909" id="rid43" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>44 : Ustekinumab, an anti-IL-12/23 p40 monoclonal antibody, inhibits radiographic progression in patients with active psoriatic arthritis: results of an integrated analysis of radiographic data from the phase 3, multicentre, randomised, double-blind, placebo-controlled PSUMMIT-1 and PSUMMIT-2 trials.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25769911" id="rid44" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>45 : Anti-IL-23A mAb BI 655066 for treatment of moderate-to-severe psoriasis: Safety, efficacy, pharmacokinetics, and biomarker results of a single-rising-dose, randomized, double-blind, placebo-controlled trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/34911706" id="rid45" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>46 : Efficacy and safety of risankizumab for active psoriatic arthritis: 24-week results from the randomised, double-blind, phase 3 KEEPsAKE 1 trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/34815219" id="rid46" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>47 : Efficacy and safety of risankizumab for active psoriatic arthritis: 24-week results from the randomised, double-blind, phase 3 KEEPsAKE 2 trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8717514" id="rid47" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>48 : CD28/B7 system of T cell costimulation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24376655" id="rid48" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>49 : Targeting CD28, CTLA-4 and PD-L1 costimulation differentially controls immune synapses and function of human regulatory and conventional T-cells.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8632801" id="rid49" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>50 : Long-term acceptance of skin and cardiac allografts after blocking CD40 and CD28 pathways.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10943858" id="rid50" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>51 : Adenovirus-mediated gene transfer of CTLA-4Ig fusion protein in the suppression of experimental autoimmune arthritis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21245206" id="rid51" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>52 : Therapeutic targeting of B cells for rheumatic autoimmune diseases.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24791010" id="rid52" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>53 : CD20+ B cell depletion in systemic autoimmune diseases: common mechanism of inhibition or disease-specific effect on humoral immunity?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32814461" id="rid53" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>54 : Anifrolumab, a monoclonal antibody to the type I interferon receptor subunit 1, for the treatment of systemic lupus erythematosus: an overview from clinical trials.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32814461" id="rid54" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>55 : Anifrolumab, a monoclonal antibody to the type I interferon receptor subunit 1, for the treatment of systemic lupus erythematosus: an overview from clinical trials.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26748580" id="rid55" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>56 : Editorial: Biosimilars: New or DéjàVu?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26964144" id="rid56" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>57 : The changing landscape of biosimilars in rheumatology.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33396369" id="rid57" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>58 : The Biosimilar Landscape: An Overview of Regulatory Approvals by the EMA and FDA.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23897773" id="rid58" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>59 : Biosimilars to treat inflammatory arthritis: the challenge of proving identity.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23687260" id="rid59" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>60 : A randomised, double-blind, parallel-group study to demonstrate equivalence in efficacy and safety of CT-P13 compared with innovator infliximab when coadministered with methotrexate in patients with active rheumatoid arthritis: the PLANETRA study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23687259" id="rid60" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>61 : A randomised, double-blind, multicentre, parallel-group, prospective study comparing the pharmacokinetics, safety, and efficacy of CT-P13 and innovator infliximab in patients with ankylosing spondylitis: the PLANETAS study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26662931" id="rid61" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>62 : Brief Report: Utilization of the First Biosimilar Infliximab Since Its Approval in South Korea.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26662931" id="rid62" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>63 : Brief Report: Utilization of the First Biosimilar Infliximab Since Its Approval in South Korea.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26150601" id="rid63" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>64 : A phase III randomised, double-blind, parallel-group study comparing SB4 with etanercept reference product in patients with active rheumatoid arthritis despite methotrexate therapy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26150601" id="rid64" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>65 : A phase III randomised, double-blind, parallel-group study comparing SB4 with etanercept reference product in patients with active rheumatoid arthritis despite methotrexate therapy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26150601" id="rid65" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>66 : A phase III randomised, double-blind, parallel-group study comparing SB4 with etanercept reference product in patients with active rheumatoid arthritis despite methotrexate therapy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26150601" id="rid66" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>67 : A phase III randomised, double-blind, parallel-group study comparing SB4 with etanercept reference product in patients with active rheumatoid arthritis despite methotrexate therapy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29411547" id="rid67" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>68 : The Science Behind Biosimilars: Entering a New Era of Biologic Therapy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27479870" id="rid68" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>69 : Bioequivalence of Biosimilar Tumor Necrosis Factor-αInhibitors Compared With Their Reference Biologics: A Systematic Review.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/37234004" id="rid69" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>70 : Therapeutic Equivalence of Biosimilar and Reference Biologic Drugs in Rheumatoid Arthritis: A Systematic Review and Meta-analysis.</p>
</a>
</div>
</div>
</div>
</div>

</section>

</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->


<!-- End Footer Area -->
<!-- Back to top -->

<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->

<!-- Prpper JS -->

<!-- Bootstrap Min JS -->

<!-- Classy Nav Min Js -->

<!-- Owl Carousel Min Js -->

<!-- Magnific Popup JS -->

<!-- CounterUp JS -->

<!-- Waypoints JS -->

<!-- Form Validator Min JS -->

<!-- Contact Form Min JS -->

<!-- Main JS -->

<!-- Global site tag (gtag.js) - Google Analytics -->






</body>
</html>
